Innate Pharma S.A. Statistics
Share Statistics
Innate Pharma S.A. has 92.16M
shares outstanding. The number of shares has increased by 3.54%
in one year.
| Shares Outstanding | 92.16M |
| Shares Change (YoY) | 3.54% |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | 0.17% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,293 |
| FTD / Avg. Volume | 5.05% |
Short Selling Information
The latest short interest is 65.67K, so 0.07% of the outstanding
shares have been sold short.
| Short Interest | 65.67K |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 1.62 |
Valuation Ratios
The PE ratio is -2.91 and the forward
PE ratio is 5.
Innate Pharma S.A.'s PEG ratio is
-0.01.
| PE Ratio | -2.91 |
| Forward PE | 5 |
| PS Ratio | 11.41 |
| Forward PS | 1.2 |
| PB Ratio | 16.3 |
| P/FCF Ratio | -19.76 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Innate Pharma S.A..
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.6,
with a Debt / Equity ratio of 3.51.
| Current Ratio | 2.6 |
| Quick Ratio | 2.6 |
| Debt / Equity | 3.51 |
| Debt / EBITDA | -0.66 |
| Debt / FCF | -4.25 |
| Interest Coverage | -91.12 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $69,729.28 |
| Profits Per Employee | $-273,320.44 |
| Employee Count | 181 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -20% in the
last 52 weeks. The beta is 0.94, so Innate Pharma S.A.'s
price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -20% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 2 |
| Relative Strength Index (RSI) | 55.24 |
| Average Volume (20 Days) | 25,621 |
Income Statement
In the last 12 months, Innate Pharma S.A. had revenue of 12.62M
and earned -49.47M
in profits. Earnings per share was -0.61.
| Revenue | 12.62M |
| Gross Profit | 12.62M |
| Operating Income | -51.58M |
| Net Income | -49.47M |
| EBITDA | -46.91M |
| EBIT | -48.91M |
| Earnings Per Share (EPS) | -0.61 |
Full Income StatementBalance Sheet
The company has 66.4M in cash and 31M in
debt, giving a net cash position of 35.4M.
| Cash & Cash Equivalents | 66.4M |
| Total Debt | 31M |
| Net Cash | 35.4M |
| Retained Earnings | -386.36M |
| Total Assets | 111.06M |
| Working Capital | 52.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -6.9M
and capital expenditures -391K, giving a free cash flow of -7.29M.
| Operating Cash Flow | -6.9M |
| Capital Expenditures | -391K |
| Free Cash Flow | -7.29M |
| FCF Per Share | -0.09 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -408.64% and -391.97%.
| Gross Margin | 100% |
| Operating Margin | -408.64% |
| Pretax Margin | -391.97% |
| Profit Margin | -391.97% |
| EBITDA Margin | -371.69% |
| EBIT Margin | -408.64% |
| FCF Margin | -57.74% |
